Zevra Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow10.70
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, KMPH shows a P/E ratio of 10.7. That is below the Healthcare sector average of 70.94. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 70.94. Zevra Therapeutics is at 10.7, which is lower that average. That is roughly 84.9% below the sector mean. Use the comparison chart on this page to see how KMPH stacks up against individual peers as well.
Investors watch KMPH's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Zevra Therapeutics's latest reading is 10.7. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Zevra Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 10.7) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 70.94, while KMPH is at 10.7. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
